Please use this identifier to cite or link to this item:
Title: Eltrombopag in pediatric chronic and refractory ITP: data from a retrospective multicenter study from Lebanon
Authors: Noun, Peter
Inati, Adlette
Raffoul, Rana
Younes, Jennifer Abi
Mardini, Joelle
Khalife, Hassan
Affiliations: Faculty of Medicine 
Keywords: Bleeding disorders
Chronic and refractory ITP, immune thrombocytopenia
Retrospective study
Issue Date: 2022-03-12
Publisher: Springer
Part of: Annals of Hematology
Volume: 101
Issue: 5
Start page: 991
End page: 997
About 20% to 30% of pediatric patients with immune thrombocytopenia (ITP) develop chronic or refractory disease lasting 12 months or more that can be challenging to treat. Eltrombopag is being used after failure of previous lines of therapy with good results at tertiary healthcare centers in Lebanon, a developing country with available multidisciplinary treatment modalities. This is a retrospective multicenter observational study that analyzed data on pediatric patients with chronic or refractory ITP who were given eltrombopag as second- or third-line therapy in 6 large referral hospitals in Beirut (country capital located in mid Lebanon), South, North, and Mount Lebanon between October 2016 and May 2020. The primary end point of the study was a proportion of patients achieving platelet counts of ≥ 50 × 109/L for at least 6 weeks without requiring rescue therapy during the observation period. Data from 36 patients treated for chronic and refractory ITP, 20 (55.6%) males and 16 (44.4%) females, were analyzed. The median age at the eltrombopag dose was 11 years (2-18 years). All the patients had failure of the first-line therapy with steroids, 3 patients received eltrombopag as second-line therapy, and the remaining patients had failure of at least 2 previous lines of therapy, including steroids. The primary end point was achieved in 21 (58.3%) of 36 patients. The treatment was discontinued in 3 patients due to no response. Hepatotoxicity and all other adverse events (headache, weakness, and diarrhea) were mild and transient. All the patients who achieved the target platelet count of ≥ 50 × 109/L maintained the response for the treatment duration, which was a minimum of 5 months up to 3 years, with median/mean observation periods of 12 months and 14 months, respectively. This study confirms the findings of randomized controlled trials that eltrombopag as second- or third-line therapy in pediatric patients with chronic and refractory ITP is effective and safe, reinforcing its role in the real-world management of these patients.
ISSN: 09395555
DOI: 10.1007/s00277-022-04804-z
Open URL: Link to full text
Type: Journal Article
Appears in Collections:Faculty of Medicine

Show full item record


checked on Apr 20, 2024

Record view(s)

checked on Apr 23, 2024

Google ScholarTM


Dimensions Altmetric

Dimensions Altmetric

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.